Pruritic dermatoses: Overview of etiology and therapy

American Journal of Medicine

Volumn 113, Issue 9 SUPPL. 1, 2002, Pages 25-33

  Charlesworth, Ernest N ^a,b   Beltrani Sr , Vincent S ^c  

^a Shannon Clinic   (United States)

^b UNIVERSITY OF TEXAS MEDICAL SCHOOL   (United States)

^c Columbia Univ School of Medicine ^*  (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIHISTAMINIC AGENT; CORTICOSTEROID; CYTOKINE; ENDORPHIN DERIVATIVE; FEXOFENADINE; HISTAMINE; IMMUNOMODULATING AGENT; INTERLEUKIN 2; KININ DERIVATIVE; LEUKOTRIENE DERIVATIVE; NEUROPEPTIDE; OPIATE; OPIATE ANTAGONIST; PROSTAGLANDIN; PROSTAGLANDIN E1; PROSTAGLANDIN E2; PROTEINASE; SEROTONIN; TUMOR NECROSIS FACTOR ALPHA;

ACUPUNCTURE; ALLERGIC DISEASE; ALLERGY; ATOPIC DERMATITIS; CANCER; CHRONIC KIDNEY DISEASE; CLINICAL TRIAL; DERMATITIS HERPETIFORMIS; DRUG EFFICACY; ENDOCRINE DISEASE; HUMAN; INFLAMMATION; MASTOCYTOSIS; NERVE STIMULATION; NEUROANATOMY; NEUROPHYSIOLOGY; PATIENT COMPLIANCE; PHOTOTHERAPY; PLASMAPHERESIS; PRIMARY BILIARY CIRRHOSIS; PRIORITY JOURNAL; PRURITUS; REVIEW; SEDATION; SKIN CARE; SKIN DISEASE; THERMAL STIMULATION; TREATMENT INDICATION; URTICARIA;

EID: 0037122433     PISSN: 00029343     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (72)

1. Savin J.A. How should we define itching? J Am Acad Dermatol. 38:1998;268-269.
2. Verbov J. No laughing matter. Br J Dermatol. 38:1998;300.
3. Armstrong CA, Scholzen T, Olerud JE, et al. Neurobiology of the skin. In: Freeberg IM, Eisen AZ, Fitzpatrick TB (Eds), Fitzpatrick's Dermatology in General Medicine, 5th edition,vol. 1. New York: McGraw-Hill, 1999:321-326.
4. Denman S.T. A review of pruritus. J Am Acad Dermatol. 14:1986;375-392.
5. Torebjork H.E., Ochoa J.L. Pain and itch from C fiber stimulation. [abstract] Soc Neurosci Abstr. 7:1981;228.
6. Melzack R.H., Schecter B. Itch and vibration. Science. 147:1965;1047-1048.
7. Melzack R.H., Wall P.D. Pain mechanisms a new theory . Science. 150:1965;971-979.
8. Heyer G., Hornstein O.P., Handwerker H.O. Skin reactions and itch sensation induced by epicutaneous histamine application in atopic dermatitis and controls. J Invest Dermatol. 93:1989;492-496.
9. Davies M.G., Greaves M.W. Sensory responses of human skin to synthetic histamine analogues and histamine. Br J Clin Pharmacol. 9:1980;461-465.
10. Simone D.A., Alreja M., LaMotte R.H. Psychophysical studies of the itch sensation and itchy skin ("alloknesis") produced by intracutaneous injection of histamine. Somatosens Mot Res. 8:1991;271-279.
11. Hagermark O. Peripheral and central mediators of itch. Skin Pharmacol. 5:1992;1-8.
12. Greaves M.W., McDonald-Gobson W. Itch the role of prostaglandins . BMJ. 3:1973;608-609.
13. Hagermark O., Strandberg K. Pruritogenic activity of prostaglandin E2. Acta Derm Venereol. 57:1977;37-43.
14. Monash S., Woessner J. Pruritus and proteolytic enzymes. Arch Dermatol. 78:1958;214-217.
15. Lerner E.A. Chemical mediators of itching. Bernhardt J.D. Itch: Mechanisms and Management of Pruritus. 1994;27-36 McGraw-Hill, New York.
16. Darsow U., Scharein E., Bromm B., Ring J. Skin testing of the pruritogenic activity of histamine and cytokines (interleukin-2 and tumour necrosis factor-alpha) at the dermal-epidermal junction. Br J Dermatol. 137:1997;415-417.
17. Soter N., Lewis R., Corey E., et al. Local effects of synthetic leukotrienes (LTC4, LTE4, LTD4, and LTB4) in human skin. J Invest Dermatol. 80:1983;115-119.
18. Willemson M.A., Lutt M.A., Sterijlen P.M., et al. Clinical and biochemical effects of zileuton in patients with the Sjögren-Larsson syndrome. Eur J Pediatr. 160:2001;711-717.
19. Gorski P., Ulinski S. Effect of occupational exposure to opiates on the respiratory system. Int J Occup Med Environ Health. 9:1996;245-253.
20. Barke K.E., Hough L.B. Opiates, mast cells and histamine release. Life Sci. 53:1993;1391-1399.
21. Stellato C., Cirillo R., dePaulis A., et al. Human mast cell releasability. IX. Heterogeneity of the effects of opioids on mediator release. Anesthesiology. 53:1993;932-940.
22. Fjellner B., Hagermark O. Potentiation of histamine-induced itch and flare responses in human skin by the enkephalin analogue FK 33-824, beta endorphin and morphine. Arch Dermatol Res. 274:1982;29-37.
23. Charlesworth E.N. Practical approaches to the treatment of atopic dermatitis. Allergy Proc. 15:1994;269-274.
24. Hanifin J.M., Rajka G. Diagnostic features of atopic dermatitis. Acta Derm Venereol (Stockh). 92:1980;44-49.
25. Koblenzer C.S. Itching and the atopic skin. J Allergy Clin Immunol. 104:1999;S109-S113.
26. Leung D.Y., Hanifin J.M., Charlesworth E.N., et al. Disease management of atopic dermatitis a practice parameter . Ann Allergy Asthma Immunol. 79:1997;197-211.
27. Charlesworth E.N. The spectrum of urticaria. All that urticates may not be urticaria. Immunol Allergy Clin North Am. 15:1995;641-657.
28. Grattan C.E.H., Charlesworth E.N. Urticaria. Holgate S.T., Church M.K., Lichtenstein L.M. Allergy. 2nd ed:2001;93-104 Mosby, St. Louis.
29. Kaplan A.P., Gray L., Shaff R.E., Horakova Z., Beaven M.A. In vivo studies of mediator release in cold urticaria and cholinergic urticaria. J Allergy Clin Immunol. 55:1975;394-402.
30. Kaplan A.P., Horakova Z., Katz S. Assessment of tissue fluid histamine levels in patients with urticaria. J Allergy Clin Immunol. 61:1978;350-354.
31. Hide M., Francis D.M., Grattan C.E.H., et al. The pathogenesis of chronic idiopathic urticaria new evidence suggests an autoimmune basis and implications for treatment . Clin Exp Allergy. 24:1994;624-627.
32. Zavadak D., Tharp M.D. Chronic urticaria as a manifestation of the late phase reaction. Immunol Allergy Clin North Am. 15:1995;745-759.
33. Charlesworth E.N. Urticaria and angioedema a clinical spectrum . Ann Allergy Asthma Immunol. 76:1996;484-496.
34. Charlesworth E.N., Kagey-Sobotka A., Norman P.S., et al. Effect of cetirizine on mast cell mediator release and cellular traffic during the cutaneous late-phase reaction. J Allergy Clin Immunol. 83:1989;905-912.
35. 1 receptor blockade on the early and late response to cutaneous allergen challenge. J Pharmacol Exp Ther. 262:1992;964-970.
36. 1 antagonist (Terfenadine) while mediator release is unaffected in vivo and in vitro. Clin Exp Allergy. 23:1993;399-405.
37. Venzor J., Baer S.C., Huston D.P. Urticarial vasculitis. Immunol Allergy Clin North Am. 15:1995;761-774.
38. Metcalfe D.D. Conclusions. Clinical advances in mastocytosis a roundtable discussion; June 15, 1990; Southampton, Bermuda . J Invest Dermatol. 96:1991;55S-59S.
39. Lauterburg B.H., Taswell H.F., Pineda A.A., Dickson E.R., Burgstaler E.A., Carolson G.L. Treatment of pruritus of cholestasis by plasma perfusion through USP-charcoal-coated glass beads. Lancet. 2:1980;53-55.
40. Neiman RS, Bischel MD, Lukes RJ. Uraemia and mast-cell proliferation [letter]. Lancet. 1972;i:959.
41. Francos G.C., Kauh Y.C., Gittlen S.D., et al. Elevated plasma histamine in chronic uremia. Effects of ketotifen on pruritus. Int J Dermatol. 30:1991;884-889.
42. Ghent C.N., Bloomer J.R., Klatskin G. Elevations in skin tissue levels of bile acids in human cholestasis relation to serum levels and to pruritus . Gastroenterology. 73:1977;1125-1130.
43. Jones E.A., Bergasa N.V. Pruritus of cholestasis and the opioid system. JAMA. 268:1992;3359-3362.
44. Metze D., Reimann S., Beissert S., Luger T. Efficacy and safety of naltrexone, an oral opiate receptor antagonist, in the treatment of pruritus in internal and dermatological diseases. J Am Acad Dermatol. 41:1999;533-539.
45. Fjellner B., Hagermark O. Pruritus in polycythaemia vera treatment with aspirin and possibility of platelet involvement . Acta Dermatol Venereol. 59:1979;505-512.
46. McGrath J.A., Greaves M.W. Aquagenic pruritus and the myelodysplastic syndrome. Br J Dermatol. 123:1990;414-415.
47. Barghuthy F.S., Kumar V., Valeski E., Beutner E.H., Chorzelski T.P. Identification of IgA subclasses in skin of dermatitis herpetiformis patients. Int Arch Allergy Appl Immunol. 85:1988;268-271.
48. Smith E.B., King C.A., Baker M.D. Crotamiton lotion in pruritus. Int J Dermatol. 23:1984;684-685.
49. Holme S.A., Mills C.M. Crotamin and narrow-band UVB phototherapy novel approaches to alleviate pruritus of breast carcinoma skin infiltration . J Pain Symptom Manage. 22:2001;803-805.
50. Yosipovitch G., Maibach H.I. Effect of pramoxine on experimentally induced pruritus in human. Am Acad Dermatol. 37:1997;278-280.
51. Weisshaar E., Heyer G., Forster C., et al. Effect of topical capsaicin on the cutaneous reactions and itching to histamine in atopic eczema compared to healthy skin. Arch Dermatol Res. 290:1998;306-311.
52. Kopecky E.A., Jacobson S., Bach M.B., et al. Safety and pharmacokinetics of EMLA in the treatment of postburn pruritus in pediatric patients a pilot study . J Burn Care Rehabil. 22:2001;235-242.
53. Smith P.F., Corelli R.L. Doxepin in the management of pruritus associated with allergic cutaneous reactions. Ann Pharmacother. 31:1997;633-635.
54. Zhai H., Frisch S., Pelosi A., et al. Antipruritic and thermal sensation effects of hydrocortisone creams in human skin. Skin Pharmacol Appl Skin Physiol. 13:2000;352-357.
55. Choi C.J., Nghiem P. Tacrolimus ointment in the treatment of chronic cutaneous graft-vs-host disease a case series of 18 patients . Arch Dermatol. 137:2001;1202-1206.
56. Rust C., Sauter G.H., Oswald M., et al. Effect of cholestyramine on bile acid pattern and synthesis during administration of ursodeoxycholic acid in man. Eur J Clin Invest. 30:2000;135-139.
57. Bergasa N.V., Alling D.W., Talbot T.L., et al. Relief from the intractable pruritus of chronic cholestasis associated with oral nalmefene therapy. [abstract] Hepatology. 14:1001;154A.
58. Harrison P.V. Nalmefene and pruritus. [letter] J Am Acad Dermatol. 23:1990;530.
59. 2 receptor antagonists, cromolyn, and ketotifen. Clin Dermatol. 18:2000;103-111.
60. Soter N.A., Austen K.F., Wasserman S.I. Oral disodium cromoglycate in the treatment of systemic mastocytosis. N Engl J Med. 301:1979;465-469.
61. Monk B.E. Transcutaneous electronic nerve stimulation in the treatment of generalized pruritus. Clin Exp Dermatol. 18:1993;67-68.
62. Gomez R.L., Griffin J.W., Squires J.E. Prolonged relief of intractable pruritus in primary sclerosing cholangiitis by plasmapheresis. J Clin Gastroenterol. 8:1986;301-303.
63. 2 antagonists for chemoprophylaxis a double-blind, placebo controlled study in healthy volunteers . J Clin Pharmacol. 37:1997;140-146.
64. 1-type antihistamines . J Am Acad Dermatol. 24:1991;1084-1087.
65. 1-Receptor Antagonists in Allergic Disease. 1996;145-174 Marcel Dekker, New York.
66. 1-Receptor Antagonists in Allergic Disease. 1996;117-144 Marcel Dekker, New York.
67. 1 receptor effects of antihistamines. Clin Exp Allergy. 29:(suppl 3):1999;39-48.
68. 1-receptor antagonists. J Allergy Clin Immunol. 107:2001;526-530.
69. Lee E.E., Maibach H.I. Treatment of urticaria: an evidence-based evaluation of antihistamines. Am J Clin Dermatol. 2:2001;27-32.
70. Boguniewicz M., Fiedler V.C., Raimer S., et al. A randomized, vehicle-controlled trial of tacrolimus ointment for treatment of atopic dermatitis in children. J Allergy Clin Immunol. 102:1998;637-644.
71. Young GL, Jewell D. Antihistamine versus aspirin for itching in late pregnancy. Cochrane Database Syst Rev. 2000;CD000027.
72. Lebwohl M. Phototherapy of pruritus. Bernhard J.D. Itch: Mechanisms and Management of Pruritus. 1994;399-412 McGraw-Hill, New York.